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A B S T R A C T
Anthocyanins are natural bioactive compounds that have several health beneﬁts. This systematic review and
meta-analysis assessed the impact of dietary anthocyanins on markers of systemic and vascular inﬂammation.
Meta-analysis of 32 randomised controlled trials indicated that dietary anthocyanins signiﬁcantly decreased
levels of C-reactive protein (CRP;−0.33mg/l, 95% CI:−0.55 to−0.11, P=0.003), interleukin-6 (IL-6;−0.41
ρg/ml, 95% CI:−0.70 to−0.13, P=0.004), tumor necrosis factor-alpha (TNF-α;−0.64 ρg/ml, 95% CI:−1.18
to −0.09, P=0.023), intercellular adhesion molecule-1 (−52.4 ng/ml, 95% CI: −85.7 to −19.1, P=0.002),
and vascular adhesion molecule-1 (VCAM-1; −49.6 ng/ml, 95% CI: −72.7 to −26.5, P < 0.001) while adi-
ponectin level was signiﬁcantly increased (0.75 μg/ml, 95% CI: 0.23 to 1.26, P=0.004). The levels of inter-
leukin-1β (IL-1β;−0.45 ρg/ml, 95% CI:−3.77 to 2.88, P=0.793) and P-selectin (−6.98 ng/ml, 95% CI:−18.1
to 4.15, P=0.219) did not signiﬁcantly change. Subgroup analyses showed that administration of higher doses
of anthocyanins (> 300mg/day) signiﬁcantly decreased levels of CRP, IL-6, TNF-α, and VCAM-1. The results
indicate that dietary anthocyanins reduce the levels of systemic and vascular inﬂammation in the subjects.
1. Introduction
Results of previous surveys have indicated the contribution of low-
grade chronic inﬂammation on the development and progression of
various non-communicable chronic diseases like diabetes mellitus type
2, chronic kidney disease, stroke, atherosclerosis, cardiovascular dis-
eases, and malignancies (Nathan, 2002; Tabas and Glass, 2013). The
inﬂammatory response is characterized by the activation of various
signaling pathways that increase expression and levels of pro-in-
ﬂammatory mediators such as C-reactive protein (CRP), interleukin-1β
(IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), in-
tercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion mo-
lecule-1 (VCAM-1), and other cytokines. Higher concentrations of pro-
inﬂammatory mediators not only predict future development of chronic
diseases, but also mediate pathogenesis of the diseases (Dinarello, 2000;
Tabas and Glass, 2013). Therefore, reduction of the levels of pro-in-
ﬂammatory mediators is one way to decrease the risk of such chronic
diseases.
Anthocyanins, a member of the ﬂavonoids family, are water-soluble
vacuolar pigments responsible for red-orange to blue-violet colors in
many fruits, vegetables, and ﬂowers. At ﬁrst, anthocyanins were only
famous for their coloring attributes inﬂuencing the sensory character-
istics of food products. But now the focus is on the health beneﬁts of
these compounds due to their biological activities (Stintzing and Carle,
2004; Norberto et al., 2013). The in vivo and in vitro studies indicated
that biological activities of anthocyanins are mainly related to their
antioxidative characteristics (Shih et al., 2010; Rugină et al., 2012;
Maciel et al., 2018; Prokop et al., 2018). Considering the fact that free
radical damage is the etiology of many chronic diseases, potential an-
tioxidative activity of anthocyanins can slow down the progression of
such diseases (Li et al., 2017).
In human clinical trials, the beneﬁcial eﬀects of dietary adminis-
tration of anthocyanins or anthocyanin-rich foodstuﬀs are reported as
follows: Prevention of cardiovascular diseases (Novotny et al., 2015),
reduction of blood pressure in hypertensive subjects (Johnson et al.,
2015), enhancement of oxidative status in healthy smokers (Park et al.,
2015), reduction of thrombogenesis in overweight and obese subjects
(Thompson et al., 2017b), bone loss protection in postmenopausal
smokers (Kaume et al., 2014), prevention of type 2 diabetes in pre-
diabetics (An et al., 2016), reduction of serum lipids in patients with
metabolic syndrome (Basu et al., 2010a), enhancement of liver function
in non-alcoholic fatty liver disease (Zhang et al., 2015), and reduction
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of fasting blood sugar and glycosylated hemoglobin in patients with
type 2 diabetes (Gorji et al., 2014).
Several human clinical trials have investigated the eﬀect of dietary
anthocyanins on inﬂammatory markers of subjects with diﬀerent health
status; however, diﬀerent results have been reported. Some studies
reported that consumption of anthocyanins reduced the levels of some
inﬂammatory markers (Curtis et al., 2009; Hassellund et al., 2013;
Asgary et al., 2016; Johnson et al., 2017). On the other hand, the other
studies found no signiﬁcant changes in the levels of inﬂammatory
markers following anthocyanins administration (Kolehmainen et al.,
2012; Li et al., 2015; Jeong et al., 2016; Chew et al., 2019). Therefore,
this study aimed to evaluate and elucidate the impact of pure antho-
cyanins or anthocyanin-rich extract/powder on serum levels of CRP, IL-
6, TNF-α, IL-1β, adiponectin, ICAM-1, VCAM-1, and P-selectin.
2. Methods
2.1. Strategy of searching
This research was conducted and the results were presented ac-
cording to the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) instructions (Moher et al., 2015). The protocol
of this research was recorded in PROSPERO, the international database
of prospectively registered systematic review in health and social care
(registry code: CRD42017068611).
Five electronic databases including PubMed, ISI Web of Science,
Scopus, MagIran, and Scientiﬁc Information Database (SID) were
searched up to 1 April 2019. The detail of search strategy is described in
Supplementary Data, Appendix A.
The search was carried out by 2 authors (AAF and TJ) in-
dependently, and the obtained articles were assessed. For screening, 3
authors (AAF, ES, and PF) separately assessed the articles through the
review of titles and abstracts; and if necessary, the full texts. After
screening, the full texts of remained articles were evaluated based on
inclusion criteria (section 2.2) to identify the studies eligible for sys-
tematic review and meta-analysis. At each stage, doubtful cases were
discussed within the research team.
2.2. Selection of studies
The inclusion criteria to choose the articles were: (a) parallel or
cross-over randomised controlled trials (RCTs) in adults (age≥ 18
years old) in which the intervention group consumed pure anthocya-
nins or anthocyanin-rich extract/powder; (b) RCTs administrated pla-
cebo in control group and pure anthocyanins or anthocyanin-rich ex-
tract/powder in intervention group; (c) RCTs that did not prescribe
placebo in control group, but the diﬀerence of this group with inter-
vention group was only administration of anthocyanins; (d) interven-
tion duration was not less than 3 weeks; (e) a quantitative or quanti-
ﬁable anthocyanin content was reported for the intervention group; (f)
RCTs provided suﬃcient information on baseline and end-trial circu-
lating and vascular markers comprising CRP, IL-6, TNF-α, IL-1β, adi-
ponectin, ICAM-1, VCAM-1, or P-selectin.
2.3. Data extraction
Two authors (AAF and ES) independently assessed the eligible RCTs,
and following items were abstracted: last name of ﬁrst author, year of
publication, country of origin, number of subjects in each group, design
and duration of RCT, daily dosage and form of anthocyanins, health
condition of participants, and concentrations of CRP, IL-6, TNF-α, IL-
1β, adiponectin, ICAM-1, VCAM-1, and P-selectin.
2.4. Quality assessment of studies and outcomes
The quality of selected RCTs was assessed by Cochrane
Collaboration's risk of bias tool that includes the following domains:
random sequence generation, allocation concealment, blinding of par-
ticipants and personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting, and other sources of bias.
For each domain, RCTs were classiﬁed into low, unclear, or high risk of
bias (Higgins and Green, 2008).
The quality of meta-analysis for each outcome was assessed by
NutriGrade scoring system that consists of the following criteria for
meta-analysis of RCTs: risk of bias, precision, heterogeneity, directness,
publication bias, funding bias, and study design. In this scoring system,
each outcome scored from 0 to 10. The scores≥8, 6–7.99, 4–5.99, and
0–3.99 were judged as high, moderate, low, and very low quality, re-
spectively (Schwingshackl et al., 2016).
2.5. Statistical methods
For each eligible RCT, the eﬀect size for CRP (mg/l), IL-6 (ρg/ml),
TNF-α (ρg/ml), IL-1β (ρg/ml), adiponectin (μg/ml), ICAM-1 (ng/ml),
VCAM-1 (ng/ml), or P-selectin (ng/ml) was computed as un-
standardized mean diﬀerence and 95% conﬁdence interval (CI). The net
mean diﬀerence in intervention or control group was calculated by the
following formula: (measure at baseline – measure at end-trial).
Standard deviation (SD) of the mean diﬀerence in intervention or
control group was calculated as follow: SD= sqrt
[(SDbaseline)2 + (SDend-trial)2− (2R×SDbaseline × SDend-trial)], sup-
posing a correlation coeﬃcient (R)= 0.50 (Fallah et al., 2018; Jafari
et al., 2018). In RCTs reporting standard error of the mean (SEM), SD
was calculated as follow: SD = SEM× sqrt (n), where n is the number
of participants. For outcomes presented as median and interquartile
range, mean and SD values were calculated according to the procedure
of Wan et al. (2014). Since the eligible RCTs were conducted in various
settings, random eﬀects were employed to account for anticipated
heterogeneity between contributing studies (DerSimonian and Laird,
1986). Study-level characteristics including duration of RCTs, antho-
cyanins doses, baseline inﬂammatory markers, and health status of the
subjects were pre-speciﬁed as characteristics for assessment of hetero-
geneity, which was conducted using stratiﬁed analysis and random
eﬀects meta-regression. Cochrane's Q tests were employed to test the
hypothesis of inter-trial heterogeneity (Higgins and Green, 2008). I-
squared (I2) index, has a range of 0–100%, was used to quantify inter-
trial heterogeneity. I2 values of 25, 50 and 75% are referred to low,
moderate, and high heterogeneity, respectively (Higgins et al., 2003).
Publication bias was evaluated by Begg and Mazumdar adjusted rank
correlation test (Begg and Mazumdar, 1994; Jafari et al., 2015) and
Egger's regression asymmetry test (Egger et al., 1997; Jafari et al.,
2017). Sensitivity analysis was performed to examine the extent to
which inferences might depend on a particular RCT or number of RCTs.
In order to conduct statistical analyses, data from selected RCTs were
entered into an Excel sheet and then imported into a Stata database
(Stata software version 11.2; Stata Corporation, College Station, TX).
Level of signiﬁcance was set at P≤ 0.050.
3. Results
3.1. Search results
We detected 3369 records in our initial systematic search, and then
excluded 1571 duplicates. After assessing the remaining records, 1673
were removed since the records were irrelevant to the topic, animal
trials, or review articles. Finally, 125 records were assessed carefully
and 32 studies (Karlsen et al., 2007; Naruszewicz et al., 2007; Curtis
et al., 2009; Basu et al., 2010a, 2014, 2018, 2010b; Stull et al., 2010;
Vidlar et al., 2010; Zhu et al., 2011; Kolehmainen et al., 2012;
Hassellund et al., 2013; Moazen et al., 2013; Riso et al., 2013; Soltani
et al., 2014; Li et al., 2015; Asgary et al., 2016; Jeong et al., 2016; Lee
et al., 2016; Loo et al., 2016; Zhang et al., 2016; Johnson et al., 2017;
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Thompson et al., 2017a; Xie et al., 2017; Yang et al., 2017; Espinosa-
Moncada et al., 2018; Kim et al., 2018; Maeda-Yamamoto et al., 2018;
Marín-Echeverri et al., 2018; Arevström et al., 2019; Chew et al., 2019;
Schell et al., 2019) comparing an intervention group (received dietary
pure anthocyanins or anthocyanins-rich extract/powder) with a control
group entered meta-analysis (Fig. 1).
3.2. Study characteristics
The main characteristics of 32 RCTs, with 1744 subjects, carried out
in Norway, Poland, United Kingdom, United States of America, Iran,
Italy, Czech Republic, China, Korea, Japan, Colombia, Sweden,
Australia, and Finland are outlined in Table 1. The dosage of antho-
cyanins was between 1.60 and 1323mg/day; and the trial duration was
between 3 and 24 weeks. The subjects were healthy in 6 RCTs (Karlsen
et al., 2007; Curtis et al., 2009; Riso et al., 2013; Thompsonet al.,
2017a; Maeda-Yamamoto et al., 2018; Chew et al., 2019), individuals
with metabolic syndrome in 7 RCTs (Basu et al., 2010a, 2010b;
Kolehmainen et al., 2012; Jeong et al., 2016; Espinosa-Moncada et al.,
2018; Kim et al., 2018; Marín-Echeverri et al., 2018), individuals with
diabetes mellitus type 2 in 4 RCTs (Moazen et al., 2013; Li et al., 2015;
Yang et al., 2017; Schell et al., 2019), overweight/obese in 4 RCTs
(Stull et al., 2010; Basu et al., 2014, 2018; Lee et al., 2016), pre-
hypertensive in 3 RCTs (Hassellund et al., 2013; Loo et al., 2016;
Johnson et al., 2017), hyperlipidemic in 2 RCTs (Soltani et al., 2014;
Asgary et al., 2016), hypercholesterolemic in 2 RCTs (Zhu et al., 2011;
Zhang et al., 2016), individuals with myocardial infarction in 2 RCTs
(Naruszewicz et al., 2007; Arevström et al., 2019), former smokers in 1
RCT (Xie et al., 2017), and individuals with lower urinary tract symp-
toms in 1 RCT (Vidlar et al., 2010).
3.3. Quality assessment of RCTs and outcomes
The results of risk of bias assessment are presented in Table 2. Al-
though all of the selected studies were randomized, the random se-
quence generation and allocation concealment were unclear in 10
(Karlsen et al., 2007; Naruszewicz et al., 2007; Curtis et al., 2009; Basu
et al., 2010a, 2014, 2010b; Stull et al., 2010; Kolehmainen et al., 2012;
Li et al., 2015; Zhang et al., 2016) and 15 (Karlsen et al., 2007;
Naruszewicz et al., 2007; Basu et al., 2010a, 2014, 2010b; Vidlar et al.,
2010; Zhu et al., 2011; Moazen et al., 2013; Li et al., 2015; Zhang et al.,
2016; Johnson et al., 2017; Thompson et al., 2017a; Espinosa-Moncada
et al., 2018; Arevström et al., 2019; Schell et al., 2019) studies, re-
spectively. Moreover, 3 studies (Loo et al., 2016; Thompson et al.,
2017a; Xie et al., 2017) for random sequence generation and 6 studies
(Curtis et al., 2009; Basu et al., 2010b; Stull et al., 2010; Kolehmainen
et al., 2012; Loo et al., 2016; Xie et al., 2017) for allocation conceal-
ment had high risk of bias. Seven RCTs (Karlsen et al., 2007; Basu et al.,
2010a, 2010b; Kolehmainen et al., 2012; Loo et al., 2016; Thompson
et al., 2017a; Xie et al., 2017) had high risk of bias based on blinding of
participants and personnel, while only 1 RCT (Loo et al., 2016) had
high risk of bias for blinding of outcome assessment. Incomplete
Fig. 1. PRISMA ﬂow diagram of study identiﬁcation, inclusion, and exclusion.
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outcome data and selective outcome reporting were sources of bias in 1
(Curtis et al., 2009) and 2 (Stull et al., 2010; Thompson et al., 2017a)
RCTs, respectively. None of the RCTs was high risk for other sources of
bias such as bias of study design, trial stopped early, extreme baseline
imbalance, and fraudulent trial. From 32 RCTs selected for meta-ana-
lysis, 23 RCTs (Naruszewicz et al., 2007; Vidlar et al., 2010; Zhu et al.,
2011; Hassellund et al., 2013; Moazen et al., 2013; Riso et al., 2013;
Basu et al., 2014, 2018; Soltani et al., 2014; Li et al., 2015; Asgary et al.,
2016; Jeong et al., 2016; Lee et al., 2016; Zhang et al., 2016; Johnson
et al., 2017; Yang et al., 2017; Espinosa-Moncada et al., 2018; Kim
et al., 2018; Maeda-Yamamoto et al., 2018; Marín-Echeverri et al.,
2018; Arevström et al., 2019; Chew et al., 2019; Schell et al., 2019)
were categorized as “Good”, 2 RCTs (Karlsen et al., 2007; Curtis et al.,
2009) as “Fair”, and 7 RCTs (Basu et al., 2010a, 2010b; Stull et al.,
2010; Kolehmainen et al., 2012; Loo et al., 2016; Thompson et al.,
2017a; Xie et al., 2017) as “Low”. The RCTs classiﬁed as “Good” had no
domain with high risk of bias, while “Fair” and “Low” classiﬁed RCTs
had at least one domain with high risk of bias (Table 2).
The quality of meta-analysis for CRP, IL-6, TNF-α, adiponectin, and
VCAM-1 was high (Table 3), which implies that further research likely
will not change the conﬁdence in the eﬀect estimates. Meta-analysis
quality was low for IL-1β, ICAM-1, and P-selectin (Table 3), which
implies that further research will provide important evidence and
probably change the eﬀect estimates.
3.4. Eﬀect of anthocyanins on CRP
There were 25 RCTs, with 1341 participants, in which the eﬀect of
dietary anthocyanins on serum CRP level was evaluated. The pooled
estimate revealed that dietary anthocyanins signiﬁcantly decreased
serum CRP level (Fig. 2: −0.33mg/l, 95% CI: −0.55 to −0.11,
P=0.003). Considering I2 index (0.0%) and Cochrane Q test
(P=0.912), a very low inter-trial heterogeneity was detected.
3.5. Eﬀect of anthocyanins on IL-6
The eﬀect of dietary anthocyanins on serum level of IL-6 was as-
sessed in 17 RCTs with 870 subjects. The pooled estimate demonstrated
a signiﬁcant decrease in serum IL-6 level following anthocyanins ad-
ministration (Fig. 3: −0.41 ρg/ml, 95% CI: −0.70 to −0.13,
P=0.004). The I2 index (10.4%) and Cochrane Q test (P=0.333) re-
vealed a low inter-trial heterogeneity.
3.6. Eﬀect of anthocyanins on TNF-α
Eighteen RCTs with 925 participants had data about the impact of
dietary anthocyanins on serum TNF-α level. The overall estimate
showed that intake of anthocyanins signiﬁcantly reduced serum TNF-α
level (Fig. 4: −0.64 ρg/ml, 95% CI: −1.18 to −0.09, P=0.023). The
Table 2
Risk of bias assessment of included randomized controlled trials according to the Cochrane guidelines.
Study Random
sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
outcome
reporting
Other
sources of
biasa
Overall
qualityb
Karlsen et al. (2007) U U H U L L L Fair
Naruszewicz et al.
(2007)
U U L L L L L Good
Curtis et al. (2009) U H L L H L U Fair
Basu et al. (2010a) U U H U L L U Low
Basu et al. (2010b) U H H U U L U Low
Stull et al. (2010) U H L L U H L Low
Vidlar et al. (2010) L U U L L L L Good
Zhu et al. (2011) L U L L L L L Good
Kolehmainen et al.
(2012)
U H H U L L U Low
Hassellund et al. (2013) L L L L L L U Good
Moazen et al. (2013) L U L L L L L Good
Riso et al. (2013) L L U U L L L Good
Basu et al. (2014) U U L L L L U Good
Soltani et al. (2014) L L L L L L L Good
Li et al. (2015) U U L L L L L Good
Asgary et al. (2016) L L L L L L L Good
Jeong et al. (2016) L L L L U L L Good
Lee et al. (2016) L L L L L L U Good
Loo et al. (2016) H H H H L L U Low
Zhang et al. (2016) U U L L L L L Good
Johnson et al. (2017) L U L L L L L Good
Thompson et al.
(2017a)
H U H L U H U Low
Xie et al. (2017) H H H U L L U Low
Yang et al. (2017) L L L L L L L Good
Basu et al. (2018) L L L L L L L Good
Espinosa-Moncada
et al. (2018)
L U L L L L L Good
Kim et al. (2018) L L L L L L U Good
Maeda-Yamamoto et al.
(2018)
L L L L L L L Good
Marín-Echeverri et al.
(2018)
L U L L L L L Good
Arevström et al. (2019) L U U L L L L Good
Chew et al. (2019) L L L L L U L Good
Schell et al. (2019) L U L L L L U Good
Abbreviations: L, low risk of bias; H, high risk of bias; U, unclear risk of bias.
a Bias of study design, trial stopped early, extreme baseline imbalance, and fraudulent trial.
b “Good” if at least 4 domains were low risk of bias, “Fair” if 3 domains were low risk of bias, “Low” if less than 3 domains were low risk of bias.
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I2 index (20.4%) and Cochrane Q test (P=0.211) indicated a low inter-
trial heterogeneity.
3.7. Eﬀect of anthocyanins on adiponectin
There were 8 RCTs, with 390 participants, in which the eﬀect of
dietary anthocyanins on serum adiponectin level was assessed. The
pooled estimate revealed a signiﬁcant increase in serum adiponectin
level following administration of anthocyanins (Fig. 5: 0.75 μg/ml, 95%
CI: 0.23 to 1.26, P=0.004). Considering I2 index (0.0%) and Cochrane
Q test (P=0.631), a very low inter-trial heterogeneity was detected.
3.8. Eﬀect of anthocyanins on IL-1β
The eﬀect of dietary anthocyanins on serum IL-1β level was assessed
in 5 RCTs with 375 subjects. The overall estimate demonstrated no
signiﬁcant change in serum IL-1β level following intake of anthocya-
nins (Supplementary Data, Appendix B, Fig. S1: −0.45 ρg/ml, 95% CI:
−3.77 to 2.88, P=0.793). Based on I2 index (0.0%) and Cochrane Q
test (P=0.969), a very low inter-trial heterogeneity was found.
3.9. Eﬀect of anthocyanins on ICAM-1
There were 9 RCTs, with 346 participants, in which the eﬀect of
dietary anthocyanins on serum ICAM-1 level was assessed. The pooled
estimate revealed a signiﬁcant decrease in serum ICAM-1 level fol-
lowing administration of anthocyanins (Fig. 6: −52.4 ng/ml, 95% CI:
−85.7 to −19.1, P=0.002). Considering I2 index (27.3%) and Co-
chrane Q test (P=0.201), a moderate inter-trial heterogeneity was
detected.
Table 3
Summary of ﬁndings with the NutriGrade scoring system.
Outcome Eﬀect size (95% CI) No. of participants (studies) Score Outcome quality
CRP −0.33mg/l (−0.55 to −0.11) 1341 (25 RCTs) 8.5 High
IL-6 −0.41 ρg/ml (−0.70 to −0.13) 870 (17 RCTs) 8.25 High
TNF-α −0.64 ρg/ml (−1.18 to −0.09) 925 (18 RCTs) 8.25 High
IL-1β −0.45 ρg/ml (−3.77 to 2.88) 375 (5 RCTs) 5.75 Low
Adiponectin 0.75 μg/ml (0.23–1.26) 390 (8 RCTs) 8 High
ICAM-1 −52.4 ng/ml (−85.7 to −19.1) 346 (9 RCTs) 5.75 Low
VCAM-1 −49.6 ng/ml (−72.7 to −26.5) 510 (11 RCTs) 8 High
P-selectin −6.98 ng/ml (−18.1 to 4.15) 222 (3 RCTs) 5.5 Low
Abbreviations: CI, conﬁdence interval; CRP, C-reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-1β, interleukin-1β; IL-6, interleukin-6; RCTs, rando-
mized controlled trials; TNF-α, tumor necrosis factor-alpha; VCAM-1, vascular adhesion molecule-1.
Fig. 2. Forest plot of the eﬀect of dietary anthocyanins on C-reactive protein.
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Fig. 3. Forest plot of the eﬀect of dietary anthocyanins on interleukin-6.
Fig. 4. Forest plot of the eﬀect of dietary anthocyanins on tumor necrosis factor-alpha.
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3.10. Eﬀect of anthocyanins on VCAM-1
The eﬀect of dietary anthocyanins on serum level of VCAM-1 was
assessed in 11 RCTs with 510 subjects. The pooled estimate demon-
strated a signiﬁcant decrease in serum VCAM-1 level following antho-
cyanins administration (Fig. 7:−49.6 ng/ml, 95% CI:−72.7 to−26.5,
P < 0.001). The I2 index (0.0%) and Cochrane Q test (P=0.630) re-
vealed a very low inter-trial heterogeneity.
3.11. Eﬀect of anthocyanins on P-selectin
The eﬀect of dietary anthocyanins on serum P-selectin level was
assessed in 3 RCTs with 222 subjects. The overall estimate demon-
strated no signiﬁcant change in serum P-selectin level following intake
of anthocyanins (Supplementary Data, Appendix B, Fig. S2: −6.98 ng/
ml, 95% CI: −18.1 to 4.15, P=0.219). Based on I2 index (0.0%) and
Cochrane Q test (P=0.755), a very low inter-trial heterogeneity was
found.
Fig. 5. Forest plot of the eﬀect of dietary anthocyanins on adiponectin.
Fig. 6. Forest plot of the eﬀect of dietary anthocyanins on intercellular adhesion molecule-1.
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3.12. Meta-regression, subgroup and sensitivity analyses
Considering the fact that intervention duration, anthocyanins dose,
baseline levels of studied markers, and health status of subjects might
inﬂuence the net changes of the markers, we performed meta-regres-
sion and subgroup analyses based on these probable confounders. Meta-
regression analysis revealed inverse association between the eﬀect sizes
of CRP (P for interaction=0.041), IL-6 (P for interaction= 0.036),
TNF-α (P for interaction= 0.038), and VCAM-1 (P for interac-
tion=0.035) and anthocyanins doses. No relation was found for other
probable confounders. Subgroup analyses revealed that intake of higher
doses of anthocyanins (> 300mg/day) signiﬁcantly decreased levels of
CRP, IL-6, TNF-α, and VCAM-1 (Table 4).
Sensitivity analyses showed that the elimination of each RCT at one
time or the simultaneous elimination of fair and low quality RCTs
(studies with high risk of bias) did not signiﬁcantly change the overall
estimates of CRP, IL-6, TNF-α, adiponectin, IL-1β, ICAM-1, VCAM-1,
and P-selectin (data not shown).
3.13. Publication bias
Based on results of Begg and Mazumdar adjusted rank correlation
test, no sign of publication bias was detected for CRP (P=0.815), IL-6
(P=0.099), TNF-α (P=0.472), adiponectin (P=0.458), IL-1β
(P=0.327), ICAM-1 (P=0.404), VCAM-1 (P=0.697), and P-selectin
(P=0.117). Moreover, results of Egger's regression asymmetry test
revealed no publication bias for CRP (P=0.316), IL-6 (P=0.607),
TNF-α (P=0.489), adiponectin (P=0.415), IL-1β (P=0.263), ICAM-
1 (P=0.564), VCAM-1 (P=0.360), and P-selectin (P=0.187).
4. Discussion
Chronic non-communicable diseases like cardiovascular events,
obesity, diabetes, and other metabolic diseases are introduced as
current phenomena of 21st century. In such diseases, a systemic and
vascular low-grade inﬂammation and increased activity of in-
ﬂammatory mediators are recognized as background. Considering the
promotion in controlling the infectious diseases, people have chance for
living longer. Along with increased longevity, the production and ac-
tivity of pro-inﬂammatory markers and free radicals increase. The anti-
inﬂammatory and antioxidative capacity of body decreases with aging,
hence taking anti-inﬂammatory or antioxidant supplements seems ne-
cessary.
CRP, an acute phase reactive protein, is produced by hepatocytes as
a result of stimulation of IL-6 that is secreted by macrophages and T-
cells. Recent evidences suggest that higher levels of CRP were asso-
ciated with increased risk of cardiovascular diseases, diabetes, and
other metabolic disorders (Windgassen et al., 2011). TNF-α, as a cy-
tokine, is produced by monocytes and adipose tissue, and induces the
inﬂammatory processes via the regulation of inﬂammatory cytokines
especially IL-6 (Liu et al., 2006). IL-1β is also recognized as a pro-in-
ﬂammatory cytokine released in response to the infection or tissue in-
juries (Lopez-Castejon and Brough, 2011). Adhesion molecules in-
cluding ICAM-1, VCAM-1, and P-selectin are mainly expressed on
surface of leukocytes and endothelial cells and mediate cell-matrix or
cell-cell interactions. These molecules have been considered as vascular
inﬂammatory markers because their levels are increased in patients
with systematic vascular inﬂammation and cardiovascular diseases
(Demerath et al., 2001; Savoia and Schiﬀrin, 2007).
Chronic low-grade inﬂammation can induce the inﬁltration of im-
mune cells into the adipose tissue and increase the production of in-
ﬂammatory mediators. The elevated levels of inﬂammatory markers in
the blood circulation may disrupt the normal metabolic functions of
cells and result in accumulation of harmful agents like free-radicals and
reactive oxygen species (ROS). Therefore, a cyclic process of in-
ﬂammation and oxidative stress is produced, which promote the risk of
cardiovascular and metabolic disorders like diabetes (Rani et al., 2016).
The nuclear factor κB (NF-κB) pathways are activated by ROS and
Fig. 7. Forest plot of the eﬀect of dietary anthocyanins on vascular adhesion molecule-1.
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Table 4
Results of the eﬀect of dietary anthocyanins on circulating and vascular inﬂammation based on meta-regression and subgroup analyses.
Outcome Variable No. of trials Eﬀect size (95% CI) I2 (%) Q-statistics (P) P for interactiona
CRP Intervention duration 0.128
≤ 8 weeks 16 −0.13mg/l (−0.48, 0.22) 0.0 0.655
> 8 weeks 9 −0.46mg/l (−0.75, −0.18) 0.0 0.949
Anthocyanins dosage 0.041
≤ 300mg/day 13 −0.09mg/l (−0.40, 0.22) 0.0 0.997
> 300mg/day 12 −0.59mg/l (−0.91, −0.27) 0.0 0.777
Baseline CRP 0.135
≤ 3mg/l 14 −0.14mg/l (−0.41, 0.13) 0.0 0.947
> 3mg/l 11 −0.73mg/l (−1.12, −0.35) 0.0 0.975
Health status 0.234
Healthy individuals 5 −0.17mg/l (−0.56, 0.22) 0.5 0.404
Individuals with impaired health 20 −0.41mg/l (−0.68, −0.14) 0.0 0.947
IL-6 Intervention duration 0.213
≤ 8 weeks 11 −0.35 ρg/ml (−0.75, 0.05) 15.8 0.293
> 8 weeks 6 −0.51 ρg/ml (−0.94, −0.08) 9.5 0.355
Anthocyanins dosage 0.036
≤ 300mg/day 10 −0.60 ρg/ml (−1.29, 0.09) 24.5 0.218
> 300mg/day 7 −0.38 ρg/ml (−0.68, −0.07) 0.0 0.466
Baseline IL-6 0.099
≤ 2 pg/ml 4 −0.21 ρg/ml (−0.63, 0.21) 0.0 0.857
> 2 pg/ml 13 −0.54 ρg/ml (−0.96, −0.11) 22.5 0.216
Health status 0.415
Healthy individuals 5 0.22 ρg/ml (−0.60, 1.04) 0.0 0.775
Individuals with impaired health 12 −0.50 ρg/ml (−0.81, −0.18) 18.1 0.266
TNF-α Intervention duration 0.188
≤ 8 weeks 10 −0.42 ρg/ml (−0.90, 0.05) 0.0 0.793
> 8 weeks 8 −1.81 ρg/ml (−3.46, −0.16) 48.5 0.059
Anthocyanins dosage 0.038
≤ 300mg/day 10 −1.02 pg/ml (−2.65, 0.51) 49.8 0.036
> 300mg/day 8 −0.52 pg/ml (−1.01, −0.03) 0.0 0.875
Baseline TNF-α 0.487
≤ 8 pg/ml 9 −0.45 ρg/ml (−0.92, 0.02) 0.0 0.924
> 8 pg/ml 9 −1.27 pg/ml (−2.97, 0.44) 51.5 0.036
Health status 0.512
Healthy individuals 5 −0.65 ρg/ml (−1.56, 0.26) 0.0 0.927
Individuals with impaired health 13 −0.67 ρg/ml (−1.46, 0.12) 41.3 0.059
Adiponectin Intervention duration 0.313
≤ 8 weeks 4 0.64 μg/ml (−0.01, 1.26) 0.0 0.648
> 8 weeks 4 0.99 μg/ml (0.05, 1.93) 7.0 0.358
Anthocyanins dosage 0.088
≤ 300mg/day 5 0.93 μg/ml (0.32, 1.55) 0.0 0.524
> 300mg/day 3 0.33 μg/ml (−0.59, 1.25) 0.0 0.639
Baseline adiponectin 0.246
≤ 5 μg/ml 4 0.96 μg/ml (0.24, 1.68) 6.7 0.360
> 5 μg/ml 4 0.48 μg/ml (−0.36, 1.26) 0.0 0.745
Health status 0.503
Healthy individuals 2 0.36 μg/ml (−0.81, 1.53) 0.0 0.539
Individuals with impaired health 6 0.84 μg/ml (0.27, 1.41) 0 0.501
ICAM-1 Intervention duration 0.142
≤ 8 weeks 5 −32.3 ng/ml (−65.6, 0.95) 0.0 0.700
> 8 weeks 4 −94.4 ng/ml (−159.4, −29.4) 38.6 0.180
Anthocyanins dosage 0.093
≤ 300mg/day 7 −3.03 ng/ml (−62.6, 56.5) 22.9 0.254
> 300mg/day 2 −66.2 ng/ml (−102.9, −29.6) 0.0 0.862
Health status 0.327
Healthy individuals 1 −18.1 ng/ml (−106.8, 70.6) – –
Individuals with impaired health 8 −56.8 ng/ml (−93.6, 20.0) 32.8 0.166
VCAM-1 Intervention duration 0.364
≤ 8 weeks 6 −40.9 ng/ml (−83.9, 2.10) 14.8 0.319
> 8 weeks 5 −54.4 ng/ml (−82.9, −25.8) 0.0 0.770
Anthocyanins dosage 0.035
≤ 300mg/day 7 −33.7 ng/ml (−75.9, 8.47) 0.0 0.737
> 300mg/day 4 −56.1 ng/ml (−96.2, −16.1) 30.0 0.232
Health status 0.621
Healthy individuals 2 −6.35 ng/ml (−72.1, 59.4) 0.0 0.423
Individuals with impaired health 9 −55.7 ng/ml (−80.3, −31.1) 0.0 0.709
Abbreviations: CI, conﬁdence interval; CRP, C-reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha;
VCAM-1, vascular adhesion molecule-1.
a P value obtained from meta-regression analysis.
A.A. Fallah, et al. Food and Chemical Toxicology xxx (xxxx) xxxx
11
support the inﬂammation by increasing the gene expression of in-
ﬂammatory markers. Anthocyanins (as potent antioxidants) trap ROS,
hence the activation of NF-κB pathways is blocked and the gene ex-
pression of inﬂammatory markers is inhibited (Chen et al., 2006;
Dembinska-Kiec et al., 2008; Rani et al., 2016).
Previous studies have demonstrated the anti-inﬂammatory eﬀects of
anthocyanins in animal models and cell cultures following induction of
inﬂammation (Atalay et al., 2003; Herath et al., 2003; Cimino et al.,
2006; Gasparrini et al., 2017, 2018; Joo et al., 2018; Sun et al., 2018).
However, the results of anthocyanins administration in human clinical
trials are controversial. Our meta-analysis revealed for the ﬁrst time
that dietary anthocyanins reduced the serum levels of CRP, IL-6, TNF-α,
ICAM-1, and VCAM-1 but not IL-1β and P-selectin in the subjects.
Takikawa et al. (2010) reported the amelioration in insulin sensitivity
and hyperglycemia in diabetic mice after administration of anthocya-
nins. They found that anthocyanins reduced gene expression of retinol
binding protein 4 (RBP4) and activated the AMP-activated protein ki-
nase (AMPK). Serum level of RBP4 increased in inﬂammatory condi-
tions and is known to be associated with obesity and insulin resistance.
AMPK, the most regulatory component of energy balance in the cells,
increased the gene expression of glucose transporter 4 (Glut4) in the
cell membrane; therefore, enhanced the glucose uptake and amelio-
rated the hyperglycemia.
Adiponectin is known as an anti-inﬂammatory marker derived from
adipose tissue. Adiponectin has some insulin-sensitizing characteristics
and decreased in the serum of insulin resistant, diabetic, and obese
subjects. Chronic inﬂammation and oxidative stress reduced the pro-
duction of adiponectin from adipocytes (Lu et al., 2008). Results of our
meta-analysis showed that dietary anthocyanins increased the serum
level of adiponectin in the participants. It has been demonstrated that
anthocyanins induced adiponectin gene expression and secretion in
adipocytes via regulation of transcriptional factor forkhead box O1 and
nuclear receptor PPAR-γ (Liu et al., 2014).
Results of this study indicate that higher doses of dietary antho-
cyanins (> 300mg/day) can aﬀect serum levels of CRP, IL-6, TNF-α,
and VCAM-1 in the participants. The dose-dependent eﬀects of dietary
anthocyanins on inﬂammatory markers are still unknown in human
clinical trials. In contrast, the anthocyanins eﬀects on inﬂammatory
markers in a dose-dependent manner are proved in some in vitro and
animal model studies (Lau et al., 2007; Ahmet et al., 2009; Liu et al.,
2014).
It has been demonstrated that anthocyanins or anthocyanins-rich
foodstuﬀs are safe and well tolerated in humans (Corcoran et al., 2012).
Side eﬀects of dietary anthocyanins are uncommon; however, 5 in-
cluded RCTs in our meta-analysis reported limited side eﬀects. Asgary
et al. (2016) found that 4 out of 20 individuals consuming whortleberry
extract capsules complained of gastrointestinal upset due to consump-
tion of capsules with empty stomach. Basu et al. (2010a) reported that 9
out of 25 participants consuming freeze-dried blueberries were with-
drawn during the ﬁrst week of study due to adverse eﬀects like nausea,
vomiting, constipation, and diarrhea. Hassellund et al. (2013) found
that from 27 individuals who consumed anthocyanins capsules, 3 cases
of minor headache, 2 cases of darker stools, and 1 case of nausea were
observed. Moazen et al. (2013) found only one case of nausea among 20
participants following the administration of freeze-dried strawberries.
Yang et al. (2017) found that from 80 individuals who consumed pure
anthocyanins capsules, 4 cases of dark stools, 1 case of diarrhea, 1 case
of dizziness, and 1 case of skin rash were observed. The other 27 RCTs
used in this study did not report adverse eﬀects in participants either in
intervention or in control groups.
This study had some limitations: (i) the eligible studies used dif-
ferent sources of dietary anthocyanins that vary in composition as well
as the contents of other bioactive compounds. This may confound the
eﬀects of anthocyanins on inﬂammatory markers; (ii) the subjects of
eligible studies had diﬀerent health status; (iii) the design of 6 studies
(Hassellund et al., 2013; Loo et al., 2016; Basu et al., 2018; Espinosa-
Moncada et al., 2018; Marín-Echeverri et al., 2018; Schell et al., 2019)
were cross-over, which diﬀers from the other studies; moreover, one of
them (Loo et al., 2016) had no wash out period for treatment eﬀects;
(iv) diﬀerent methods and instruments were used to measure the in-
ﬂammatory and anti-inﬂammatory markers, which may aﬀect the re-
sults.
These are some strengths of this meta-analysis: (i) this is the ﬁrst
study assessing the eﬃcacy of dietary anthocyanins on inﬂammatory
and anti-inﬂammatory markers following a comprehensive systematic
search; (ii) since the quality of pooled estimates for CRP, IL-6, TNF-α,
VCAM-1, and adiponectin was high, the obtained results are reliable.
5. Conclusions
Results of this study demonstrate that dietary anthocyanins sig-
niﬁcantly decreased CRP, IL-6, TNF-α, ICAM-1, and VCAM-1 levels,
while adiponectin level was signiﬁcantly increased. Dietary anthocya-
nins did not signiﬁcantly change IL-1β and P-selectin levels in the
subjects. Our results also demonstrated that administration of higher
doses of anthocyanins (> 300mg/day) are more eﬀective to reduce the
levels of CRP, IL-6, TNF-α, and VCAM-1. We recommend more clinical
trials with diﬀerent durations and doses in patients with various levels
of inﬂammation to elucidate the eﬀects of dietary anthocyanins on in-
ﬂammatory and anti-inﬂammatory markers.
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